Cargando…

Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B

BACKGROUND: In the phase 3 B‐LONG study (NCT01027364), prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) every 7 to >14 days was associated with low annualized bleed rates (ABRs) in males aged ≥12 years with severe hemophilia B. The long‐term safety and efficacy of rFIXFc prophyla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shapiro, Amy D., Pasi, K. John, Ozelo, Margareth C., Kulkarni, Roshni, Barnowski, Christopher, Winding, Bent, Szamosi, Johan, Lethagen, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles: Haemostasis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332734/ https://www.ncbi.nlm.nih.gov/pubmed/30656283 http://dx.doi.org/10.1002/rth2.12163

Ejemplares similares

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2023)

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies
por: Chowdary, Pratima, et al.
Publicado: (2022)

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2019)

Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis
por: Shapiro, Amy D., et al.
Publicado: (2023)

Performance of factor IX extended half‐life product measurements in external quality control assessment programs
por: Nederlof, Angelique, et al.
Publicado: (2020)

Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX‐Padua
por: Robinson, Mary M., et al.
Publicado: (2021)

Joint status of patients with nonsevere hemophilia A
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study
por: Abdi, Amal, et al.
Publicado: (2021)

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort
por: Pasi, K. John, et al.
Publicado: (2021)

Validation of PROMIS Profile‐29 in adults with hemophilia in the Netherlands
por: van Balen, Erna C., et al.
Publicado: (2021)

Probing activation‐driven changes in coagulation factor IX by mass spectrometry
por: Freato, Nadia, et al.
Publicado: (2021)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972–2019
por: Hassan, Shermarke, et al.
Publicado: (2021)

Genetic analysis of carrier status in female members of Japanese hemophilia families
por: Shinozawa, Keiko, et al.
Publicado: (2021)

The experiences and attitudes of hemophilia carriers around pregnancy: A qualitative systematic review
por: Punt, Marieke C., et al.
Publicado: (2020)

Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018
por: Hassan, Shermarke, et al.
Publicado: (2020)

First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results
por: Königs, Christoph, et al.
Publicado: (2022)

F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes
por: Branchini, Alessio, et al.
Publicado: (2021)

Validity and reliability of the Colorado Adult Joint Assessment Scale in adults with moderate‐severe hemophilia A
por: Funk, Sharon M., et al.
Publicado: (2019)

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
por: Valke, Lars L.F.G., et al.
Publicado: (2020)

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand
por: Álvarez-Román, María-Teresa, et al.
Publicado: (2023)

Hydrogen‐deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa
por: Bar Barroeta, Awital, et al.
Publicado: (2019)

Detailed analysis of anti‐emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A
por: Kaneda, Makoto, et al.
Publicado: (2021)

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
por: Klamroth, Robert, et al.
Publicado: (2019)

Impact of prophylaxis on health‐related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries
por: Usuba, Koyo, et al.
Publicado: (2019)

Fusion of engineered albumin with factor IX Padua extends half‐life and improves coagulant activity
por: Lombardi, Silvia, et al.
Publicado: (2021)

Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study
por: Oldenburg, Johannes, et al.
Publicado: (2019)

Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice
por: van der Flier, Arjan, et al.
Publicado: (2023)

Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
por: Coyle, T E, et al.
Publicado: (2014)

Real‐world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years
por: Shapiro, Amy, et al.
Publicado: (2020)

Adenovirus‐associated antibodies in UK cohort of hemophilia patients: A seroprevalence study of the presence of adenovirus‐associated virus vector–serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A
por: Stanford, Sophia, et al.
Publicado: (2019)

Temperature‐dependent irreversible conformational change of recombinant ADAMTS13 upon metal ion chelation
por: Rottensteiner, Hanspeter, et al.
Publicado: (2019)

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults
por: Konkle, Barbara A., et al.
Publicado: (2023)

Fibrinogen αC‐regions are not directly involved in fibrin polymerization as evidenced by a “Double‐Detroit” recombinant fibrinogen mutant and knobs‐mimic peptides
por: Duval, Cédric, et al.
Publicado: (2020)

Prolonged APTT of unknown etiology: A systematic evaluation of causes and laboratory resource use in an outpatient hemostasis academic unit
por: Barbosa, Ayla Cristina Nóbrega, et al.
Publicado: (2019)

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa
por: Lentz, S R, et al.
Publicado: (2014)

High use of pain, depression, and anxiety drugs in hemophilia: more than 3000 people with hemophilia in an 11-year Nordic registry study
por: Steen Carlsson, Katarina, et al.
Publicado: (2023)

Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A
por: Rejtő, Judit, et al.
Publicado: (2020)

Blockade of the costimulatory CD28‐B7 family signal axis enables repeated application of AAV8 gene vectors
por: Frentsch, Marco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_iuroq7q74uq8leamt3lna67iri